A Study of MHB118C Injection in Patients With Advanced Solid Tumors

Summary

This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB118C monotherapy.

Timeline

Start

2025-03-31

Primary completion

2029-03

Completion

2031-03

Drugs

Indications